Review of pharmacotherapy options for the treatment of attention-deficit/hyperactivity disorder (ADHD) and ADHD-like symptoms in children and adolescents with developmental disorders

Developmental Disabilities Research Reviews

Volumn 16, Issue 3, 2010, Pages 273-282

  Rowles, Brieana M ^a   Findling, Robert L ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Attention deficit hyperactivity disorder; Developmental disorder; Subaverage intelligence; Treatment

Indexed keywords

ALCOHOL; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; ATOMOXETINE; CLONIDINE; DEXAMPHETAMINE; DONEPEZIL; FENFLURAMINE; GUANFACINE; LEVACECARNINE; METHYLPHENIDATE; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; RISPERIDONE; THIORIDAZINE; TUBERIN; ZIPRASIDONE; AMPHETAMINE DERIVATIVE; CENTRAL STIMULANT AGENT; NEUROLEPTIC AGENT; PROPYLAMINE; PSYCHOTROPIC AGENT;

ATTENTION DEFICIT DISORDER; AUTISM; BEDTIME DOSAGE; CHILD; COMORBIDITY; CRYING; DEVELOPMENTAL DISORDER; DISEASE ASSOCIATION; DOWN SYNDROME; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FETAL ALCOHOL SYNDROME; FRAGILE X SYNDROME; GASTROINTESTINAL SYMPTOM; GENETIC DISORDER; HUMAN; INTELLIGENCE QUOTIENT; IRRITABILITY; LOW DRUG DOSE; MENTAL INSTABILITY; MULTICENTER STUDY (TOPIC); NEUROFIBROMATOSIS; PRENATAL EXPOSURE; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPONSE TIME; REVIEW; SIDE EFFECT; SLEEP DISORDER; STEREOTYPY; TUBEROUS SCLEROSIS; WEIGHT GAIN; WILLIAMS BEUREN SYNDROME; ADOLESCENT; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; FEMALE; GENETICS; MALE; MENTAL DEFICIENCY; PREGNANCY; PRESCHOOL CHILD; PSYCHOLOGICAL ASPECT;

ADOLESCENT; AMPHETAMINES; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; CLONIDINE; COMORBIDITY; DEVELOPMENTAL DISABILITIES; DRUG THERAPY, COMBINATION; FEMALE; FETAL ALCOHOL SYNDROME; HUMANS; MALE; MENTAL RETARDATION; METHYLPHENIDATE; PREGNANCY; PROPYLAMINES; PSYCHOTROPIC DRUGS;

EID: 79952788922     PISSN: 19405510     EISSN: 10982779     Source Type: Journal    
DOI: 10.1002/ddrr.120     Document Type: Review

References (57)

1. Agarwal V, Sitholey P, Kumar S, et al. 2001. Double-blind, placebo-controlled trial of cloni-dine in hyperactive children with mental retardation. Ment Retard 39:259-267.
2. Aman MG, Farmer CA, Hollway J, et al. 2008. Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 17: 713-738.
3. Aman MG, Kern RA, McGhee DE, et al. 1993. Fenfluramine and methylphenidate in children with mental retardation and ADHD: clinical and side effects. J Am Acad Child Adolesc Psychiatry 32:851-859.
4. Aman MG, Marks RE, Turbott SH, et al. 1991. Clinical effects of methylphenidate and thio-ridazine in intellectually subaverage children. J Am Acad Child Adolesc Psychiatry 30: 246-256.
5. Arnold LE, Aman MG, Cook AM, et al. 2006. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 45:1196-1205.
6. Bawden HN, MacDonald GW, Shea S. 1997. Treatment of children with Williams syndrome with methylphenidate. J Child Neurol 12:248-252.
7. Berry-Kravis E, Potanos K. 2004. Psychopharmacology in fragile X syndrome-present and future. Ment Retard Dev Disabil Res Rev 10:42-48.
8. Capone GT, Goyal P, Ares W, et al. 2006. Neurobehavioral disorders in children, adolescents, and young adults with Down syndrome. Am J Med Genet C Semin Med Genet 142C:158-172.
9. Capone GT, Goyal P, Grados M, et al. 2008. Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study. J Dev Behav Pediatr 29: 106-116.
10. Coe J, Sidders J, Riley K, et al. 2001. A survery of medication responses in children and adolescents with fetal alcohol syndrome. Ment Health Aspects Dev Disabil 4:148-155.
11. Conner DF, Rubin J. 2010. Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents. Drugs Today (Barc) 46:299-314.
12. Correia Filho AG, Bodanese R, Silva TL, et al. 2005. Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation. J Am Acad Child Adolesc Psychiatry 44:748-755.
13. Curatolo P, Verdecchia M, Bombardieri R. 2002. Tuberous sclerosis complex: a review of neurological aspects. Eur J Paediatr Neurol 6: 15-23.
14. D'Agati E, Moavero R, Cerminara C, et al. 2009. Attention-deficit hyperactivity disorder (ADHD) and tuberous sclerosis complex. J Child Neurol 24:1282-1287.
15. Doig J, McLennan JD, Gibbard WB. 2008. Medication effects on symptoms of attention-deficit/hyperactivity disorder in children with fetal alcohol spectrum disorder. J Child Adolesc Psychopharmacol 18:365-371.
16. Doyle RL, Frazier J, Spencer TJ, et al. 2006. Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series. J Atten Disord 9:543-549.
17. Duggal HS. 2007. Ziprasidone for maladaptive behavior and attention-deficit/hyperactivity disorder symptoms in autistic disorder. J Child Adolesc Psychopharmacol 17:261-263.
18. Dykens EM. 2007. Psychiatric and behavioral disorders in persons with Down syndrome. Ment Retard Dev Disabil Res Rev 13: 272-278.
19. Findling RL. 2008. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review. Clin Ther 30:942-957.
20. Frazier JA, Biederman J, Bellordre CA, et al. 2001. Should the diagnosis of attention-deficit/hyperactivity disorder be considered in children with pervasive developmental disorder? J Atten Disord 4:203-211.
21. Ghuman JK, Aman MG, Lecavalier L, et al. 2009. Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. J Child Adolesc Psychopharmacol 19:329-339.
22. Goforth HW, Rao MS. 2003. Improvement in behavior and attention in an autistic patient treated with ziprasidone. Aust N Z J Psychiatry 37:775-776.
23. Hagerman RJ, Murphy MA, Wittenberger MD. 1988. A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet 30:377-392.
24. Handen BL, Breaux AM, Gosling A, et al. 1990. Efficacy of methylphenidate among mentally retarded children with attention deficit hyper-activity disorder. Pediatrics 86:922-930.
25. Handen BL, Breaux AM, Janosky J, et al. 1992. Effects and noneffects of methylphenidate in children with mental retardation and ADHD. J Am Acad Child Adolesc Psychiatry 31:455-461.
26. Handen BL, Feldman HM, Lurier A, et al. 1999. Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD. J Am Acad Child Adolesc Psychiatry 38:805-182.
27. Handen BL, Johnson CR, Lubetsky M. 2000. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 30:245-255.
28. Handen BL, McAuliffe S, Janosky J, et al. 1995. Methylphenidate in children with mental retardation and ADHD: effects on independent play and academic functioning. J Dev Phys Disabil 7:91-103.
29. Handen BL, Sahl R, Hardan AY. 2008. Guanfacine in children with autism and/or intellectual disabilities. J Dev Behav Pediatr 29:303-308.
30. Herman LE, Acosta MC, Chang PN. 2008. Gender and attention deficits in children diagnosed with a fetal alcohol spectrum disorder. Can J Clin Pharmacol 15:e411-e419.
31. Hilton DK, Martin CA, Heffron WM, et al. 1991. Imipramine treatment of ADHD in a fragile X child. J Am Acad Child Adolesc Psychiatry 30:831-834.
32. Hyman SL, Shores EA, North KN. 2006. Learning disabilities in children with neurofibro-matosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. Dev Med Child Neurol 48:973-977.
33. Jaselskis CA, Cook EH Jr, Fletcher KE, et al. 1992. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 12:322-327.
34. Kaufmann R, Goldberg-Stern H, Shuper A. 2009. Attention-deficit disorders and epilepsy in childhood: incidence, causative relations and treatment possibilities. J Child Neurol 24:727-733.
35. Koth CW, Cutting LE, Denckla MB. 2000. The association of neurofibromatosis type 1 and attention deficit hyperactivity disorder. Child Neuropsychol 6:185-194.
36. Kratochvil CJ, Vaughan BS, Barker A, et al. 2009. Review of pediatric attention deficit/hyper-activity disorder for the general psychiatrist. Psychiatr Clin N Am 32:39-56.
37. Leskovec TJ, Rowles BM, Findling RL. 2008. Pharmacological treatment options for autism spectrum disorders in children and adolescents. Harv Rev Psychiatry 16:97-112.
38. Leyfer OT, Woodruff-Borden J, Klein-Tasman BP, et al. 2006. Prevalence of psychiatric disorders in 4 to 16-year-olds with Williams syndrome. Am J Med Genet B Neuropsychiatr Genet 141B:615-622.
39. Mautner VF, Kluwe L, Thakker SD, et al. 2002. Treatment of ADHD in neurofibromatosis type 1. Dev Med Child Neurol 44:164-170.
40. Mick E, Biederman J, Faraone SV, et al. 2002. Case-control study of attention-deficit/hyper-activity disorder and maternal smoking, alcohol use, and drug use during pregnancy. J Am Acad Child Adolesc Psychiatry 14:378-385.
41. Myers BA, Pueschel SM. 1991. Psychiatric disorders in persons with Down syndrome. J Nerv Ment Dis 179:609-613.
42. O'Malley KD, Koplin B, Dohner VA. 2000. Psychostimulant clinical response in fetal alcohol syndrome. Can J Psychiatry 45:90-91.
43. Oesterheld JR, Kofoed L, Tervo R, et al. 1998. Effectiveness of methylphenidate in Native American children with fetal alcohol syndrome and attention deficit/hyperactivity disorder: a controlled pilot study. J Child Adolesc Psychopharmacol 8:39-48.
44. Payton JB, Burkhart JE, Hersen M, et al. 1989. Treatment of ADDH in mentally retarded children: a preliminary study. J Am Acad Child Adolesc Psychiatry 28:761-767.
45. Pearson DA, Santos CW, Roache JD, et al. 2003. Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD. J Am Acad Child Adolesc Psychiatry 42:209-216.
46. Pliszka S;AACAP Work Group on Quality Issues. 2007. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46: 894-921.
47. Posey DJ, Puntney JI, Sasher TM, et al. 2004. Guan-facine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 14:233-241.
48. Posey DJ, Wiegand RE, Wilkerson J, et al. 2006. Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 16:599-610.
49. Power TJ, Blum NJ, Jones SM, et al. 1997. Brief report: response to methylphenidate in two children with Williams syndrome. J Autism Dev Disord 27:79-87.
50. Quintana H, Birmaher B, Stedge D, et al. 1995. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 25:283-294.
51. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. 2005. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 62:1266-1274.
52. Scahill L, Aman MG, McDougle CJ, et al. 2006. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 16:589-598.
53. Torrioli MG, Vernacotola S, Mariotti P, et al. 1999. Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. Am J Med Genet 87:366-368.
54. Torrioli MG, Vernacotola S, Peruzzi L, et al. 2008. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A 146:803-812.
55. Troost PW, Steenhuis MP, Tuynman-Qua HG, et al. 2006. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol 16:611-619.
56. Wigal T, Greenhill L, Chuang S, et al. 2006. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry 45:1294-1303.
57. Yoshida Y, Uchiyama T. 2004. The clinical necessity for assessing attention deficit/hyperactivity disorder (AD/HD) symptoms in children with high-functioning pervasive developmental disorder (PDD). Eur Child Adolesc Psychiatry 13:307-314.